Acetohexamide

Source: Wikipedia, the free encyclopedia.
Acetohexamide
Clinical data
Trade namesDymelor
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa602021
ATC code
Pharmacokinetic data
Protein binding90%
Identifiers
  • 1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamide
JSmol)
Melting point188 to 190 °C (370 to 374 °F)
  • O=C(NC1CCCCC1)NS(=O)(=O)c2ccc(C(=O)C)cc2
  • InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19) checkY
  • Key:VGZSUPCWNCWDAN-UHFFFAOYSA-N checkY
  (verify)

Acetohexamide (trade name Dymelor) is a first-generation

diabetes mellitus type 2, particularly in people whose diabetes cannot be controlled by diet alone.[1]

Mechanism of action

Acetohexamide bind to an

pancreatic beta cells. This inhibits the out flux of potassium, which causes the membrane potential to become more positive. This depolarization in turn opens voltage-gated calcium channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of insulin.[2]

Risks

Oral hypoglycemic drugs, including acetohexamide, have been associated with increased

cardiovascular mortality. Qualified healthcare professionals should consulted for possible risks, benefits, and alternatives of using this drug for treatment of type 2 diabetes.[3]

References

  1. .
  2. ^ "Acetohexamide". DrugBank.
  3. ^ "Acetohexamide". Medline Plus. Archived from the original on 11 September 2005.